All results
1 results for impact
-
ITN095AI DESIGNATE
This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis.…
- Ages
- 8 Years - 45 Years
- Sexes
- All